Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02801760 · ClinicalTrials.gov registry record
Self-Consent for PrEP Perspectives
A clinical trial, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 58
- Enrollment target
NCT02801760: Completed study, sponsored by University of North Carolina, Chapel Hill.
NCT02801760 is a clinical trial that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 58 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02801760 has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 58 participants
- Enrollment target
Study Summary
This study involves a one-time, web-based quantitative structured self-complete ("web-based") survey for all subjects and a qualitative semi-structured ("qualitative") interview for a selected sub-sample of subjects to evaluate the consent processes in association with research outcomes, specifically early adherence to Pre-exposure Prophylaxis (PrEP) and Human Immunodeficiency Virus (HIV) seroconversion at any point during participation in the ATN 110 or ATN 113 study.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2015-11 |
| Est. Completion | 2016-03 |
What the finished NCT02801760 record still lists
NCT02801760 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 58 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02801760 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02801760 about?
NCT02801760 is a clinical study titled "Self-Consent for PrEP Perspectives". This study involves a one-time, web-based quantitative structured self-complete ("web-based") survey for all subjects and a qualitative semi-structured ("qualitative") interview for a selected sub-sample of subjects to evaluate the consent processes in association with research outcomes, specificall...
What is the current status of trial NCT02801760?
This trial is currently completed. The enrollment target is 58 participants. The study started on 2015-11. Estimated completion is 2016-03.
Who is sponsoring clinical trial NCT02801760?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia